ClinicalTrials.gov
ClinicalTrials.gov Menu

A Comparison Of The Pharmacokinetics Of PF-04191834 Following Single Dose Administration Of A Dispersion Formulation And A Suspension Formulation In Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01265732
Recruitment Status : Withdrawn
First Posted : December 23, 2010
Last Update Posted : October 16, 2015
Sponsor:
Information provided by:
Pfizer

Brief Summary:
This study investigates the safety, tolerability and pharmacokinetics of PF-04191834 when respectively given orally as a single dispersion dose and a single dose of a suspension. The suspension is the test formulation and the dispersion is the formulation with which the novel preparation will be compared.

Condition or disease Intervention/treatment Phase
Healthy Drug: PF-04191834 Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: An Open Label, Randomized 3-Way Crossover Single Dose Study To Compare The Pharmacokinetics And Relative Bioavailability Of PF-04191834 Using An Oral Wet-Milled Suspension Formulation Versus An Oral Single Dose Dispersion Formulation Under Fasted Conditions In Healthy Volunteers
Study Start Date : December 2010
Estimated Primary Completion Date : January 2011
Estimated Study Completion Date : January 2011

Arm Intervention/treatment
Active Comparator: oral single dose dispersion 100mg
Subjects receive a single dose of PF-04191834 as a dispersion
Drug: PF-04191834
single dose, 100mg, dispersion

Active Comparator: oral wet milled suspension 100mg
Subjects receive a single dose of PF-04191834 as a suspension
Drug: PF-04191834
single dose, 100mg, suspension

Active Comparator: oral wet milled suspension 300mg
Subjects receive a single dose of PF-04191834 as a suspension
Drug: PF-04191834
single dose, 300mg, suspension




Primary Outcome Measures :
  1. Time of maximum concentration(Tmax) of PF-04191834 in plasma. [ Time Frame: 3 days ]
  2. Area under the curve (AUClast) from the time of dosing to the last data point taken for PF-04191834. [ Time Frame: 3 days ]
  3. Area under the curve from the time of dosing extrapolated to infinity(AUCinf) of PF-04191834. [ Time Frame: 3 days ]

Secondary Outcome Measures :
  1. Maximum concentration (Cmax) for PF-04191834 in plasma. [ Time Frame: 3 days ]
  2. Elimination half-life (t1/2) of PF-04191834 [ Time Frame: 3 days ]
  3. Sheehan suicidality tracking scale (SSTS) [ Time Frame: Screening and last Day of Period 3 ]
  4. Number of adverse events in patients as a measure of safety and tolerability. [ Time Frame: Throughout the study. ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy male and/or female subjects of non-childbearing potential between the ages of 18 and 55 years, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG or clinical laboratory tests.
  • Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg(110 lbs).

Exclusion Criteria:

  • Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
  • Clinical evidence of existing hepatic disease or a medical history of such a condition in the last year. Subjects with AST or ALT >ULN. Subjects with total bilirubin >ULN (except those with a documented history of Gilbert's Syndrome). Subjects with AST/ALT/total bilirubin >ULN and <1.5X ULN may be retested once.
  • Treatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medication;
  • Use of tobacco- or nicotine-containing products in excess of the equivalent of 5 cigarettes per day;
  • Females of childbearing potential.
  • Subjects with positive responses (score 1) for suicidality on the Sheehan Suicidality Tracking Scale (S-STS) (specifically items 1a, 1b, 3, 4, 5, 6, 7, or 9).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01265732


Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer

Additional Information:
Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc.
ClinicalTrials.gov Identifier: NCT01265732     History of Changes
Other Study ID Numbers: B0041012
First Posted: December 23, 2010    Key Record Dates
Last Update Posted: October 16, 2015
Last Verified: October 2015

Keywords provided by Pfizer:
Phase 1
relative bioavailability
healthy volunteers
pharmacokinetics
suspension
dispersion